JPWO2010117035A1 - Composite, production method thereof, granule and tablet - Google Patents

Abstract

A composite comprising ibuprofen or a salt thereof and aluminum hydroxide, wherein ibuprofen is amorphous ibuprofen.

Description

  The present invention relates to a composite in which the dissolution property of ibuprofen is improved and the bitterness is masked, a method for producing the same, and a granule and a tablet containing the composite.

  Although ibuprofen is widely used for antipyretic analgesics and cold medicines, it has a unique bitter taste and has a problem in ingestion. Bitter taste masking has generally been improved by coating and granulation of ibuprofen particles.However, there is a problem that elution of ibuprofen decreases when coating and granulation are performed at a level that provides sufficient masking properties. there were. Therefore, the effect may be delayed for headaches that need to be corrected as soon as possible. This tendency is particularly noticeable when tablets are dissolved in the oral cavity and taken without water, such as orally disintegrating tablets and chewable tablets, and it is extremely possible to achieve both practical dissolution and bitterness masking properties. It was difficult.

JP 2008-037863 A JP 2008-007496 A

  The present invention has been made in view of the above circumstances, and an object thereof is to provide a composite containing ibuprofen, a method for producing the same, and a granule and a tablet containing the composite containing ibuprofen, which are compatible with the dissolution property and bitterness masking property of ibuprofen. And

  As a result of intensive investigations to achieve the above object, the present inventors have found that the elution and bitterness masking properties of ibuprofen can be achieved by using a composite containing amorphous ibuprofen and aluminum hydroxide. It has been found and the present invention has been made. Furthermore, it has been found that by using this complex in combination with thaumatin and / or crospovidone having a median diameter of less than 30 μm, a significant bitterness masking effect of ibuprofen can be obtained, and the present invention has been made. is there.

Accordingly, the present invention provides the following composite, a production method thereof, a granule and a tablet.
[1]. A composite comprising ibuprofen or a salt thereof and aluminum hydroxide, wherein ibuprofen is amorphous ibuprofen.
[2]. [1] The composite according to [1], wherein aluminum hydroxide is dispersed in an ibuprofen solution comprising ibuprofen or a salt thereof and a solvent, and then the solvent is distilled off.
[3]. The composite according to [1] or [2], wherein the oil absorption of aluminum hydroxide is 1 mL / g or more.
[4]. A granule containing the complex according to any one of [1] to [3] or complex particles containing the complex and thaumatin.
[5]. [1] A granule containing the composite according to any one of [3] or composite particles containing the composite, and crospovidone having a median diameter of less than 30 μm.
[6]. A tablet comprising the complex according to any one of [1] to [3] or complex particles containing the complex and thaumatin.
[7]. A tablet comprising the complex according to any one of [1] to [3] or complex particles containing the complex, and crospovidone having a median diameter of less than 30 μm.
[8]. The tablet according to [6] or [7], wherein the tablet is an orally disintegrating tablet, an orally dissolving tablet or a chewable tablet.
[9]. The method for producing a complex according to [1], wherein aluminum hydroxide is dispersed in an ibuprofen solution composed of ibuprofen or a salt thereof and a solvent, and then the solvent is distilled off.

  ADVANTAGE OF THE INVENTION According to this invention, the composite_body | complex containing ibuprofen and the manufacturing method of the same which makes the dissolution property and bitterness masking property of ibuprofen compatible, and the granule and tablet with which this was mix | blended can be provided.

2 is a chart showing thermal analysis (DSC) results of particles of Example 1. FIG.

  Hereinafter, the present invention will be described in detail. The composite of the present invention contains ibuprofen or a salt thereof and aluminum hydroxide, and ibuprofen is amorphous ibuprofen.

[Ibuprofen or its salt]
Examples of ibuprofen or a salt thereof include ibuprofen (2- (4-isobutyphenyl) propionic acid) and its salts such as sodium, potassium, magnesium, calcium, ammonium, methylglucamine, and salts with amino acids such as lysine. Can be mentioned. Ibuprofen or a salt thereof is effective as an antipyretic analgesic, but has a problem in dissolution and has a bitter taste. The compounding amount of ibuprofen in the complex and the preparation (granulate and tablet) is appropriately selected based on the OTC drug approval reference amount so that the daily dose is 450 mg.

[Aluminum hydroxide]
Aluminum hydroxide serves as a support for amorphized ibuprofen. As aluminum hydroxide, it is preferable to use aluminum hydroxide having an oil absorption of 1 mL / g or more, more preferably 1.2 mL / g or more. If the oil absorption is less than 1 mL / g, the amorphous stability may be insufficient. The upper limit of the oil absorption amount is not particularly limited, but if the oil absorption amount is too large, there may be a problem in the productivity of the composite, and 7 mL / g or less is preferable. As for the compounding quantity to the composite and formulation (a granule and a tablet) of ibuprofen, the mass ratio represented by ibuprofen / aluminum hydroxide is preferably 1 / 0.5 to 7, and more preferably 1/1 to 4.

  It is preferable to use only aluminum hydroxide as the carrier for the amorphous ibuprofen, but other carrier components and aluminum hydroxide can be used in combination as long as the effects of the present invention are not impaired. Examples of other carrier components include light anhydrous silicic acid and calcium carbonate. When a mixed carrier is used, the amount of aluminum hydroxide in the carrier is preferably 70 to 100% by mass, and more preferably 85 to 100% by mass.

  In addition, other components of ibuprofen can be used as supported components as long as the effects of the present invention are not impaired. When using other supported components, the amount of ibuprofen in the supported components is preferably 70 to 100% by mass, and more preferably 85 to 100% by mass.

  Other supported components include naproxen, ketoprofen, acetaminophen, indomethacin, bufexamac, aspirin, diclofenac, alclofenac, fenclofenac, etodolac, flurbiprofen, ketoprofen, mefenamic, meclofenamic, piroxicam Non-steroidal anti-inflammatory agents such as nitrazepam, triazolam, phenobarbital, and amibarbital; hypnotics and sedatives such as phenytoin, metalbital, primidone, clonazepam, carbamazepine, valproic acid, etc .; meclizine hydrochloride, dimenhydrinate, etc. Antidepressants; antidepressants such as imiplanin, noxiptillin, phenelzine; haloperidol, meprobamate, chlordiazepoxide, diazebam, oxazeba , Sulpiride and other neuropsychiatric agents; papaverine, atropine, etomidine and other antispasmodic agents; digoxin, digitoxin, methyldigoxin, ubidecalenone and other arrhythmic agents; pindolol, adimarin, disopyramide and other arrhythmic agents; Diuretics such as bumetanide; antihypertensives such as reserpine, dihydroergotoxin mesylate, prazosin hydrochloride, metoprolol, propranolol, atenolol; coronary vasodilators such as nitroglycerin, isosorbide nitrate, diltiazem, nifedipine, dipyridamole; noscapine, salbutamol, Antitussives such as procaterol, turopterol, tranilast, ketotifen; bromhexine hydrochloride, ambroxol hydrochloride, guaifenesi Expectorants such as nicardipine and pinpocetine; cerebral circulation improving agents such as erythromycin, josamycin, chloramphenicol, tetracycline, rifampicin and griseofulvin; antihistamines such as diphenhydramine, promethazine, mequitazine and clemastine fumarate; triamcinolone and dexamethasone Steroids such as betamethasone, betamethasone, prednisolone, danazol, methyltestosterone, chlormadinone acetate; vitamins such as vitamin A, vitamin B, vitamin C, vitamin D, vitamin E, vitamin K, folic acid (vitamin M) Agents: Dimethicone, famotidine, ranitidine, cimetidine, nizatidine, metoclopramide, famotidine, omeprazole, sulpiride, trepibutone, sucralfer Gastrointestinal disease therapeutic agents such as caffeine, dicoumarol, cinnarizine, clofibrate, gefarnate, brobenesid, mercaptopurine, methotrexate, ursodeoxycholic acid, dihydroergotamine mesylate, glucuronolactone, γ-amino Physiologically active substances such as butyric acid, chondroitin, sodium chondroitin sulfate, lactoferrin, milk protein, cysteine, collagen; starch, pregelatinized starch, sucrose, gelatin, gum arabic powder, methylcellulose, carmellose, carmellose calcium, carmellose sodium, Hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, pullulan, dextrin, carmellose, carmellose calcium, carmellose natri Um, croscarmellose sodium, carboxymethylcellulose calcium, low-substituted hydroxypropylcellulose, lactose, corn starch, talc, crystalline cellulose (Avicel, etc.), powdered sugar, mannitol, light anhydrous silicic acid, calcium carbonate, L-cysteine, stearic acid Excipients such as magnesium, calcium stearate, polyethylene glycol, talc, stearic acid, sucrose fatty acid esters, binders, disintegrants, lubricants; menthol, limonene, plant essential oils (mint oil, mint oil, lychee oil, orange) Flavors such as oil, lemon oil); sweeteners such as saccharin sodium, aspartame, stevia, dipotassium glycyrrhizinate, acesulfame potassium, sucralose; citric acid, tartaric acid, malic acid, succinic acid, fumaric acid, lactic acid It can be used acidulants such as salts thereof. These can be used individually by 1 type or in combination of 2 or more types.

[Complex]
For example, the complex is a method in which aluminum hydroxide is dispersed or dissolved in an ibuprofen solution composed of ibuprofen or a salt thereof and a solvent, and then the solvent is distilled off. An aluminum hydroxide gel is added to ibuprofen or a salt thereof, and the mixture is melted by heating. It can be obtained by, for example, a method of cooling after cooling and solidifying. Thus, ibuprofen or a salt thereof is once dissolved and reprecipitated using aluminum hydroxide as a carrier, so that ibuprofen is non-crystallized and a composite in which amorphous ibuprofen is supported on aluminum hydroxide is obtained. Non-crystallization can be confirmed from the fact that a diffraction peak derived from an ibuprofen crystal is not observed with a thermal analysis (DSC) diffractometer.

  In particular, the method of distilling off the solvent is preferable, and the solvent for dissolving ibuprofen or a salt thereof is not particularly limited as long as it can dissolve ibuprofen or a salt thereof, but a solvent such as ethanol, methanol, acetone, acetonitrile, water, aqueous sodium hydroxide, etc. Can be used alone or in combination of two or more. Although the ibuprofen density | concentration in an ibuprofen solution will not be specifically limited if it can melt | dissolve, it is 0.1-50 mass%.

  Aluminum hydroxide is added to this solution and dispersed or dissolved. From the point of impregnation with ibuprofen or a salt thereof to make it amorphous, the mass ratio represented by ibuprofen / aluminum hydroxide is preferably 1 / 0.5 to 7, and more preferably 1/1 to 4. If the amount of aluminum hydroxide relative to ibuprofen is less than 0.5, the amorphous stability may be insufficient, and the dissolution property may be poor. Further, since the amount of ibuprofen in the composite decreases when the amount of aluminum hydroxide increases, the amount of particles may increase in order to obtain an effective amount of ibuprofen.

  After the dispersion or dissolution, the obtained liquid is evaporated. The method for distilling off the solvent is not particularly limited, and a known method such as an evaporator can be used. The obtained composite can be pulverized, granulated, or sized as it is or as necessary to obtain composite particles having a predetermined particle diameter. The volume average particle diameter of the particles is preferably from 0.1 to 800 μm, more preferably from 1 to 600 μm. In addition, the measurement of the average particle diameter in this invention uses the particle size distribution measuring apparatus by a laser diffraction scattering method.

  The composite is usually “as it is, or, if necessary, within the range where the effects of the present invention are not impaired, and / or a granulated product to which other components are added” , Composite particles) ”. In this case, the ratio of the composite is 30 to 100% by mass in the composite particle, more preferably 50 to 100% by mass, and still more preferably 70 to 100% by mass. As said other component, the component quoted by [0014] is mentioned, for example.

  Using the composite or composite particle of the present invention as a core particle, a coating solution or dispersion selected from ethylcellulose, triacetin, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinylpyrrolidone, pregelatinized starch, and gelatin is separately sprayed. It is good also as a coating particle by drying and coating. Thereby, interaction with other components, etc. can be reduced. The concentration of the coating agent in the solution or dispersion is preferably 0.1 to 50% by mass, and more preferably 1 to 20% by mass. The granulating apparatus used for coating is not particularly limited, and a Wurster type fluidized bed granulator or the like is appropriately selected. The supply air temperature during flow is preferably 40 to 90 ° C, and the exhaust temperature is preferably 20 to 40 ° C. The drying temperature and time are not particularly limited, and the drying is performed at 40 to 80 ° C. for about 1 to 120 minutes. The amount of the coating agent can be performed within a range that does not significantly impair the effects of the present invention.

[Granule and tablets]
The composite or composite particle of the present invention can be blended to prepare a granule or tablet preparation containing the composite. In particular, when the tablet is an orally disintegrating tablet, an orally dissolving tablet, or a chewable tablet that can be chewed and taken in the mouth, the effect of the present invention is remarkably exhibited. The compounding quantity of a composite_body | complex is suitably selected according to the intake amount of the said ibuprofen or its salt, and aluminum hydroxide. For example, in the case of 2 tablets at a time and the mass ratio of ibuprofen to aluminum hydroxide (ibuprofen / aluminum hydroxide) is 1/1, the amount of the complex per tablet is 150 mg.

  In the preparation containing the complex or the composite particle, thaumatin and / or crospovidone having a median diameter of less than 30 μm is blended, whereby the bitterness of ibuprofen is remarkably suppressed by the synergistic effect with the complex or the composite particle. Show the effect. In particular, the combined use of thaumatin and crospovidone having a median diameter of less than 30 μm further suppresses the bitter taste of ibuprofen. Saumatine is a type of protein, also known as thaumatin. Although thaumatin is usually mixed with powder, when ibuprofen is granulated, it may be mixed in the granulated particles. Moreover, 0.01-50 mass parts is preferable with respect to 100 mass parts of ibuprofen, 0.01-1.0 mass part is more preferable, and 0.01-0.10 mass part is especially preferable with respect to 100 mass parts of ibuprofen. . Within this range, the effect of suppressing bitterness can be obtained effectively.

  Examples of crospovidone having a median diameter of less than 30 μm include Kollidon CL-F, CL-SF, CL-M manufactured by BASF, and polyplastidone INF-10 manufactured by ISP. Further, crospovidone having a median diameter of 30 μm or more can be pulverized according to a conventional method. The lower limit of the median diameter is not particularly set, but is usually preferably 1 μm or more. The amount of crospovidone having a median diameter of less than 30 μm is preferably 0.1 to 150 parts by mass, more preferably 0.5 to 120 parts by mass, and particularly preferably 1 to 100 parts by mass with respect to 100 parts by mass of ibuprofen. Within this range, the effect of suppressing bitterness can be obtained effectively.

  In the preparation, in addition to the composite or composite particles, the components to be added to the preparation can be used singly or in appropriate combination of two or more, as long as the effects of the present invention are not impaired. be able to. The following are mentioned as another component.

  Examples of excipients include cellulose and derivatives thereof, starch and derivatives thereof, saccharides, sugar alcohols, and the like. More specifically, crystalline cellulose, lactose, sucrose, mannitol, erythritol, corn starch, potato starch, hydroxy And propyl starch.

  Examples of the binder include hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, polyvinyl alcohol, polyvinylpyrrolidone, gelatin, dextrin, starch, pregelatinized starch and the like.

  Examples of the disintegrant include carmellose, carmellose calcium, croscarmellose sodium, low-substituted hydroxypropylcellulose, low-substituted carboxymethyl starch sodium, and crospovidone having a median diameter of 30 μm or more.

  Examples of the lubricant include magnesium stearate, calcium stearate, sucrose fatty acid ester, anhydrous silicic acid, light anhydrous silicic acid, sodium stearyl fumarate and the like.

  For example, the preparation can be made into a granule by mixing a complex and an optional component, and then wrapping the mixture, and the mixture can be compression molded with a rotary tableting machine, a single-punch tableting machine, or the like. In addition, a sugar coating or a pigment-containing coating can be appropriately formed into tablets.

  EXAMPLES Hereinafter, although an Example and a comparative example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example. In the following examples, unless otherwise specified, “%” in the composition represents mass%, “part” represents mass part, and the ratio represents mass ratio.

[Example 1]
100 g of crystalline ibuprofen was dissolved in 200 g of ethanol. 50 g of dry aluminum hydroxide gel was added thereto to make a uniform slurry, and then the solvent was distilled off with a rotary evaporator. When the crystallinity of the residue was evaluated with a thermal analyzer manufactured by Rigaku Denki Co., Ltd., no melting peak derived from ibuprofen crystals was observed, and ibuprofen was amorphous. The residue was sieved with a sieve of 150 to 355 μm to obtain particles having a volume average particle diameter of 200 μm.
In addition, the chart which shows the thermal analysis (DSC) result of the particle | grains of Example 1 is shown in FIG.

[Examples 2 to 5, Comparative Examples 1 to 4]
Particles were obtained in the same manner as in Example 1 except that the dry aluminum hydroxide gel was changed to the components and amounts shown in Tables 1 and 2. The crystallinity of the particles was evaluated with a thermal analyzer manufactured by Rigaku Corporation. The crystal or amorphization of ibuprofen is as shown in the table.
Was. In addition, when there is a description of the amount of thaumatin (Saneigen FFI Sun Sweet T-147) or sucralose (Saneigen FFI Slarose) in the table, these are added and mixed, and granular An agent was obtained.

[Example 6]
After adding 50 g of dry aluminum hydroxide gel to 100 g of crystalline ibuprofen, ibuprofen was melted with stirring in a 90 ° C. water bath. The molten dispersion was put into a stainless steel vat and cooled to room temperature, and the solidified product was pulverized in a mortar. When the crystallinity of the solidified product was evaluated by a thermal analyzer manufactured by Rigaku Corporation, no melting peak derived from ibuprofen crystals was observed, and ibuprofen was amorphous.

[Comparative Example 5]
100 g of crystalline ibuprofen, 100 g of dry aluminum hydroxide gel and 0.05 g of thaumatin were placed in a plastic bag and mixed by shaking 30 times by hand. When the crystallinity of the mixture was evaluated with a thermal analyzer manufactured by Rigaku Corporation, a melting peak derived from ibuprofen crystals was observed, and ibuprofen was crystalline.

[Comparative Example 6]
The particles obtained in Comparative Example 5 were used as core particles, an aqueous dispersion of 20% ethyl cellulose and 3% triacetin was used as a coating solution, and an air supply temperature was 70 using an MP-01 Wurster type fine particle coating apparatus (manufactured by POWREC). Granulation was performed at a temperature of 30 ° C. and an exhaust temperature of 30 ° C., followed by quenching at 80 ° C. for 1 hour to obtain coating particles. The coating rate was 15 parts with respect to 100 parts in total of ibuprofen and dry aluminum hydroxide gel. The coating agent is not listed in the table.

[Examples 7 to 16]
The compositions shown in Tables 3 and 4 were mixed and tableted with a tableting tester at a tableting pressure of 400 kg to obtain an orally disintegrating tablet with a diameter of 10 mm.

[Comparative Example 7]
An orally disintegrating tablet was obtained in the same manner as in Example 8, except that the composite particles obtained in Example 2 were changed to the coating particles obtained in Comparative Example 6.

The following evaluation was performed about the obtained granule and the orally disintegrating tablet. The results are also shown in the table.
<Inhibition of bitterness>
Eight specialist panels dissolved 20 g of granule and an orally disintegrating tablet in an amount of 75 mg as the amount of ibuprofen in the mouth. After discharging the dissolved material, sensory evaluation was performed according to the following evaluation criteria. Results are shown as average values.
1 point: very bitter 2 points: quite bitter 3 points: bitter 4 points: somewhat bitter 5 points: not bitter

<Elution properties of ibuprofen>
According to the JP General Test Method, a citrate buffer solution having a pH of 4.5 was used as the eluate, and the granule in an amount of 75 mg as the amount of ibuprofen and the orally disintegrating tablet were dissolved, and the dissolution rate at 10 minutes was calculated. . A result is shown by the elution rate and the following reference | standard.
◎: Elution rate 70% or more ○: Elution rate 55% or more and less than 70%

[Examples 17 to 21]
The composite particles of Examples 1, 2, 5, 6 and 7 were used as core particles, and an aqueous dispersion of 20% ethyl cellulose and 3% triacetin was used as a coating solution, and MP-01 Wurster type fine particle coating apparatus (manufactured by Paulek) The mixture was granulated at an air supply temperature of 70 ° C. and an exhaust temperature of 30 ° C., and then quenched at 80 ° C. for 1 hour to obtain coating particles. The coating rate was 15 parts with respect to 100 parts in total of ibuprofen and dry aluminum hydroxide gel. All ibuprofen of these coating particles were amorphous, and both bitterness and dissolution were excellent as in Examples 1-16.

[Example 22]
100 g of crystalline ibuprofen was dissolved in 200 g of ethanol. To this, 100 g of dry aluminum hydroxide gel and 50 g of magnesium aluminate metasilicate were added to form a uniform slurry, and then the solvent was distilled off with a rotary evaporator. When the crystallinity of the residue was evaluated with a thermal analyzer manufactured by Rigaku Denki Co., Ltd., no melting peak derived from ibuprofen crystals was observed, and ibuprofen was amorphous. The residue was sieved with a sieve of 150 to 355 μm to obtain composite particles having an average particle diameter of 200 μm.

[Example 23]
A mixture having the following composition was prepared using the composite particles obtained in Example 22, and 422.55 mg of this mixture was tableted with a tableting tester at a tableting pressure of 400 kg to obtain an orally disintegrating tablet with a diameter of 10 mm. .
Mixture composition composite particles (Example 22) 187.5 g
150 g of crystalline cellulose (Theolas KG801)
Crospovidone (Polyplusdon INF-10) 80g
Somachin 0.05g
Magnesium stearate 5g
Total 422.55g

[Example 24]
Composite particles were obtained in the same manner as in Example 22 except that 100 g of ibuprofen, 200 g of dry aluminum hydroxide gel, and 100 g of magnesium aluminate metasilicate were used. The obtained composite particles were granulated by the same method as in Example 17 to obtain coating particles.

[Example 25]
A mixture having the following composition was prepared using the coating particles obtained in Example 24, and 457.6 mg of this mixture was tableted with a tableting tester at a tableting pressure of 400 kg to obtain an orally disintegrating tablet with a diameter of 10 mm. .
Mixture composition coated particles (Example 24) 172.5 g
Acetaminophen coating * 85 g
140 g of D-mannitol
Crospopidone (Kollidon CL) 50g
Somachin 0.05g
Magnesium stearate 10g
Total 457.55g
* Coated product of acetaminophen; acetaminophen was granulated and coated in the same manner as in Example 17. The coating rate was 15 parts by mass with respect to 100 parts by mass of acetaminophen.

[Example 26]
Composite particles were obtained in the same manner as in Example 18 except that 100 g of ibuprofen, 100 g of dry aluminum hydroxide gel, and 200 g of magnesium aluminate metasilicate were used. The obtained composite particles were granulated by the same method as in Example 17 to obtain coating particles.

[Example 27]
A mixture having the following composition was prepared using the coating particles obtained in Example 26, and 470 mg of this mixture was tableted with a tableting tester at a tableting pressure of 400 kg to obtain an orally disintegrating tablet with a diameter of 10 mm.
345 g of mixture composition coated particles (Example 26)
Fructose 100g
Crospopidone (Kollidon CL-SF) 20g
Somachin 0.05g
Sucralose 0.3g
Magnesium stearate 5g
Fragrance 0.5g
Total 470.85g
The ibuprofen in the composite particles obtained in Examples 22 to 27 was amorphous, and the bitterness and elution were excellent as in Examples 1 to 16.

The raw materials used in the examples are shown below. In addition, the compounding quantity of an Example is a pure conversion amount.

Claims (9)

  A composite comprising ibuprofen or a salt thereof and aluminum hydroxide, wherein ibuprofen is amorphous ibuprofen.   The composite according to claim 1, wherein aluminum hydroxide is dispersed in an ibuprofen solution comprising ibuprofen or a salt thereof and a solvent, and then the solvent is distilled off.   The composite according to claim 1 or 2, wherein the oil absorption of aluminum hydroxide is 1 mL / g or more.   A granule containing the complex according to any one of claims 1 to 3, or complex particles containing the complex, and thaumatin.   A granule containing the composite according to any one of claims 1 to 3, or composite particles containing the composite, and crospovidone having a median diameter of less than 30 µm.   A tablet comprising the complex according to any one of claims 1 to 3, or complex particles containing the complex, and thaumatin.   A tablet comprising the composite according to any one of claims 1 to 3, or composite particles containing the composite, and crospovidone having a median diameter of less than 30 µm.   The tablet according to claim 6 or 7, wherein the tablet is an orally disintegrating tablet, an orally dissolving tablet or a chewable tablet.   The method for producing a composite according to claim 1, wherein the aluminum hydroxide is dispersed in an ibuprofen solution comprising ibuprofen or a salt thereof and a solvent, and then the solvent is distilled off.

Images